Mr. McGahan brings more than two decades of executive leadership experience across the healthcare, pharmaceutical, and life sciences sectors, with a distinguished track record in corporate governance, compliance, and regulatory strategy. He most recently served as Executive Vice President, Chief Legal Officer, and Corporate Secretary at Spectrum Pharmaceuticals (NASDAQ: SPPI), where he guided the company […]
Chuck Karan, Ph.D., serves as Chief Scientific Officer at Nouveau Biosciences, where he oversees the development of a comprehensive scientific platform spanning drug discovery to clinical trials. Dr. Karan holds a Ph.D. in Organic Chemistry from the University of Rochester. He is a leader in novel assay and technology development, contributing to both academic and […]
Mr. Turgeon brings more than 38 years of experience in the pharmaceutical and biotechnology industries, with a career distinguished by leadership in oncology drug development, global sales and marketing, and product strategy. He most recently served as President, Chief Executive Officer, and Director of Spectrum Pharmaceuticals, where he successfully guided the company’s operations and strategic […]
Mr. Elmasri is a CPA and seasoned business professional with 20 years of experience in financial and management consulting. Mr. Elmasri began his career at PricewaterhouseCoopers(“PwC”) and worked on several of the firm’s Fortune 500 clients, primarily focused on the Life Sciences and Pharmaceutical industry. From PwC, he transitioned to lead advisory practices at boutique […]
Owen is the Founder, Chair and Chief Executive Officer of Nouveau Biosciences. Under his leadership, Nouveau Biosciences has matured a platform to drug focused biotechnology company leveraging the latest advances in synthetic lethality screens, genomics and computational biology to produce a pipeline of novel, derisked nanotherapeutic drugs for cancer. Their lead drug candidate, kromastat, has […]